Free Trial
→ A deadly mistake in my prediction… (From Porter & Company) (Ad)

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Written by MarketBeat Staff
May 18, 2023

Key Points

  • Biotech stocks have a reputation for being high risk, high reward.
  • Many of the stocks Wall Street thinks can double (or better) over the next 12 months are biotechs.
  • Although Denali has yet to commercialize a product, analysts are encouraged by its progress and collaborations with major biopharmaceutical players.
  • Since its May 4th report, seven analysts have reiterated buy ratings on Ultragenyx compared to one hold.
  • Interested in Denali Therapeutics? Here are five stocks we like better.

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Upgrade Now See Benefits

Already have an account? Log in here.

Should You Invest $1,000 in Denali Therapeutics Right Now?

Before you consider Denali Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.

While Denali Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Denali Therapeutics (DNLI)
4.5021 of 5 stars		$23.50+1.3%N/A-8.51Moderate Buy$38.00
Ultragenyx Pharmaceutical (RARE)
4.7213 of 5 stars		$42.49-1.8%N/A-6.57Moderate Buy$92.43
Sarepta Therapeutics (SRPT)
4.9612 of 5 stars		$117.51+0.5%N/A94.01Moderate Buy$178.71
Pfizer (PFE)
4.9972 of 5 stars		$26.79-0.3%6.27%36.20Moderate Buy$31.92
Exelixis (EXEL)
4.8876 of 5 stars		$32.60-0.4%N/A20.90Moderate Buy$36.06
Moderna (MRNA)
4.6868 of 5 stars		$44.94+7.9%N/A-7.72Hold$69.79
United Therapeutics (UTHR)
4.8237 of 5 stars		$370.85+0.3%N/A16.29Moderate Buy$378.36
Biogen (BIIB)
4.722 of 5 stars		$145.49-2.2%N/A13.14Hold$228.80
Sanofi (SNY)
3.4099 of 5 stars		$52.97-0.7%2.79%27.03Strong Buy$60.00
Eli Lilly and Company (LLY)
4.9881 of 5 stars		$804.87-0.4%0.65%87.01Moderate Buy$997.22
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

7 Stocks to Benefit From Trump’s Tariffs in 2025

7 Stocks to Benefit From Trump’s Tariffs in 2025

While the impact of these tariffs remains uncertain, some stocks are positioned to thrive under these policies; check out these 7 stock picks now.

Recent Videos

Nuclear Energy’s Comeback: 7 Stocks to Watch in 2025
Pelosi Bets Big on AI: Her Top 5 Stock Picks
Risk vs. Reward: Why Analysts Predict Big Gains for Struggling SMCI

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines